-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- ...
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (APGE),, a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...
Zumilokibart in atopic dermatitis (AD) advancing in Phase 2 APEX trials with goal of Phase 3 initiation by end of 2026:- Part A maintenance (52-week) data readout expected in Q1 2026 with potential to ...
(RTTNews) - Tectonic Therapeutics, Inc. (TECX), a clinical-stage biotechnology company, reported fourth-quarter and full-year 2025 results and provided an update on the progress of its clinical ...
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for ...
Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology ...
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results